4. **Maskell NA**, Lee YC, Gleeson FV, *et al.* Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. *Am J Respir Crit Care Med* 2004;**170**:377–82.
5. **Ferrer J**, Montes JF, Villarino MA, *et al.* Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. *Chest* 2002;**122**:1018–27.
6. **Kennedy L**, Harley RA, Sahn SA, *et al.* Talc slurry pleurodesis. Pleural fluid and histologic analysis. *Chest* 1995;**107**:1707–12.
7. **Werebe EC**, Pazetti R, Milanez DC Jr, *et al.* Systemic distribution of talc after intrapleural administration in rats. *Chest* 1999;**115**:190–3.
8. **Dresler CM**, Olak J, Herndon JE, *et al.* Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. *Chest* 2005;**127**:909–15.
9. **Wagenfeld L**, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. *N Engl J Med* 2007;**357**:1264–5.
10. **Olivares-Torres CA**, Laniado-Laborin R, Chavez-Garcia C, *et al.* Iodopovidone pleurodesis for recurrent pleural effusions. *Chest* 2002;**122**:581–3.
11. **Janssen JP**, Collier G, Astoul P, *et al.* Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. *Lancet* 2007;**369**:1535–9.
12. **Lee YC**, Teixeira LR, Devin CJ, *et al.* Transforming growth factor-beta2 induces pleurodesis significantly faster than talc. *Am J Respir Crit Care Med* 2001;**163**:640–4.
13. **Lee YC**, Lane KB, Parker RE, *et al.* Transforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complications. *Thorax* 2000;**55**:1058–62.
14. **Lee YC**, Yasay JR, Johnson JE, *et al.* Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep. *Respirology* 2002;**7**:209–16.
15. **Light RW**, Cheng DS, Lee YC, *et al.* A single intrapleural injection of transforming growth factor-beta(2) produces an excellent pleurodesis in rabbits. *Am J Respir Crit Care Med* 2000;**162**:98–104.
16. **Kishi K**, Homma S, Sakamoto S, *et al.* Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. *Eur Respir J* 2004;**24**:263–6.
17. **Luh KT**, Yang PC, Kuo SH, *et al.* Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. *Cancer* 1992;**69**:674–9.
18. **Ren S**, Terman DS, Bohach G, *et al.* Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. *Chest* 2004;**126**:1529–39.
19. **Tremblay A**, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. *Chest* 2006;**129**:362–8.
20. **Tremblay A**, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. *Eur Respir J* 2007;**30**:759–62.
21. **Musani AI**, Haas AR, Seijo L, *et al.* Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. *Respiration* 2004;**71**:559–66.
22. **Putnam JB Jr**, Walsh GL, Swisher SG, *et al.* Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. *Ann Thorac Surg* 2000;**69**:369–75.
23. **Saffran L**, Ost DE, Fein AM, *et al.* Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. *Chest* 2000;**118**:417–21.

Are we understanding the respiratory effects of traffic related airborne particles?

Francesco Forastiere, Annunziata Faustini

There is convincing scientific evidence showing that ambient particulate matter (PM) is related to both short and long term health effects. Increased mortality and hospitalisation for cardiopulmonary causes have been noted in several studies evaluating the effects of PM₁₀ or PM_{2.5} (PM <10 or 2.5 µm in diameter).¹ However, urban air pollution consists of a complex mixture of gases and particulate agents that vary over time and through space, depending on its sources, distance and meteorological conditions.² Much of the scientific interest has been devoted to the toxicology of the ultrafine fraction of airborne particles (<0.1 µm).³ These particles are usually emitted from combustion sources (eg, gasoline or diesel powered engines) or are formed from chemical conversion of gases in the atmosphere. They are relatively short lived and combine into larger particles between 0.1 and about 1 µm in diameter (accumulation mode). These particles tend to penetrate deeper in the alveolar part of

the lung and have a larger surface area than larger sized particles, eliciting greater potential interaction with human tissues and a stronger inflammatory reaction. The epidemiological evidence linking ultrafine particles with respiratory health effects is still limited and controversial. In the current issue of *Thorax*, Halonen and colleagues⁴ provide new and compelling evidence on the respiratory effects of particles of various sizes that will certainly stimulate further research (*see page 635*).

Different sized particles were measured daily in Helsinki over a period of 7 years, and a source apportionment method was applied to separate the PM_{2.5} fraction from four sources (traffic, long range transport, soil and road dust, and coal/oil combustion). Daily counts of asthma emergency room visits among children, and asthma/chronic obstructive pulmonary disease (COPD) emergency room visits among adults and the elderly were collected. After careful control for time varying confounding factors, ultrafine particles, CO and NO₂ were strongly associated with asthma in children with a delay of 3–5 days. In contrast, asthma and COPD in the elderly were clearly associated with larger particles (accumulation mode, PM_{2.5}, coarse particles), and

CO and NO₂ at immediate lag (same day). Traffic related particles had a strong delayed effect on children's emergency room visits for asthma whereas traffic related and long range transported particles had an immediate effect on asthma/COPD visits of the elderly.

There are several strengths of the paper: a new approach to study the effect of air pollution that combines specificity in the exposure assessment (daily measurements with a differential mobility particle sizer), consideration of the pollution sources and specificity in the age groups corresponding to different respiratory conditions. The authors also give interesting indications for understanding the toxicology of particulate matter. Two aspects need to be discussed in light of the differences between asthma and COPD regarding their baseline obstructive and inflammatory characteristics: the timing of the effects that characterise the response to air pollutants in patients with asthma and in COPD patients, and the difference in the size of the particles eliciting the effects.

Childhood asthma is characterised by reversible airflow obstruction, bronchial hyperresponsiveness and an underlying inflammation. The study by Halonen and colleagues⁴ stresses the delayed role of ultrafine particles on this condition. There are other epidemiological observations with similar findings. Two time series studies on emergency room visits or hospitalisations for childhood asthma in the USA⁵ and Copenhagen⁶ support the delayed effect of ultrafine particles. The delayed effects found in these studies, including the Finnish investigation, apparently are at odds with recent

Department of Epidemiology, Rome E Health Authority, Rome, Italy

Correspondence to: Dr Francesco Forastiere, Department of Epidemiology, Rome E Health Authority, Via Santa Costanza 53, 00198 Rome, Italy; forastiere@asplazio.it

results from a field study in London where patients with asthma walking on Oxford Street had an immediate decline in lung function in response to fine and ultrafine particles from diesel traffic, higher than those walking in Hyde Park.⁷ A study by Delfino and colleagues⁸ indicated an immediate increase in exhaled nitric oxide (an established biomarker of airway inflammation) in children with asthma in relation to elemental carbon and other indicators of traffic related air pollution.

As Halonen and colleagues⁴ are aware, there are probably several reasons for the differences between studies that show an immediate effect on inflammation and lung function in patients with asthma and studies indicating a delayed effect on emergency room visits: there is a large underlying population distribution of asthma sensitivity and severity, asthma medication (inhaled bronchodilators and corticosteroids) may reverse the symptoms of air pollution and finally behavioural reasons may play a role, as not all families immediately recognise the severity of their child's symptoms. Nevertheless, a real lag time is likely between exposure to ultrafine particles and acute respiratory symptoms requiring emergency care because inflammatory events in the lungs develop over a range of hours to days. In addition, ultrafine particles may increase bronchial reactivity, secondary to airway inflammation, which may subsequently trigger symptoms after exposure to a variety of other environmental exposures.⁹

Unlike asthma, COPD is associated with irreversible airways obstruction and chronic airways inflammation with increasing frequency and severity of exacerbations.¹⁰ Fine and large particles may act as inflammatory agents with an abrupt increase in airways resistance, and worsen expiratory flow limitation and dynamic hyperinflation. The declining clinical status may require prompt emergency care for more severe forms of the disease, especially when it is accompanied by cardiac dysfunction. Moreover, systemic inflammation in response to the oxidative stress induced by PM exposure has been suggested in patients with COPD^{11–12} that may be responsible for acute cardiovascular morbidity. It is not surprising then that several studies have found an acute effect of PM₁₀ or PM_{2.5} on COPD emergency room visits or hospital care,^{13–16} although in some cases an effect was not found¹⁷ or a delayed lag was detected.¹⁸

As in most time series studies that measure daily variations in different air

pollutants, fixed monitoring stations represent daily variations in overall population exposure. However, a differential exposure misclassification for different pollutants or size fractions may influence the results when the effects are compared. For example, vehicular traffic constitutes the most significant source of ultrafine particles near roads and the variability in exposure can be much higher than in background areas. Although Halonen and colleagues⁴ indicate a reassuringly high correlation between outdoor and indoor concentrations of ultrafine particles, these results need confirmation in other areas with different environmental and urban conditions.

The possibility of generalising the findings from this study to other urban contexts is limited because of the varying nature of the pollutant mix generated from traffic. Other areas in Europe tend to have a much higher proportion of diesel powered vehicles than Nordic countries. As has been already suggested,¹⁹ evaluating the health effects of particle size alone is difficult as it is not independent of its chemical composition. The different chemical compounds of PM (eg, transition metals) may contribute differently to the PM induced health effects. There is a need for a large data set that should include the size of the particles, their sources and their chemical composition. Although the study in Helsinki offers an important insight in this direction, it is a "one city" study and the results should be replicated in different contexts. Therefore, we are only approaching an understanding of the problem. What Europe clearly needs is a multi-city study, similar to the APHEA in the 1990s,²⁰ to evaluate the short term health effects of particles of different size, their sources and compositions.²¹ The health data and ability to perform such studies are readily available, but time series of concentration levels of size fractions, chemical compositions and inventory of source contribution are not. While a large PM specialisation programme is ongoing in the USA,²² Europe is lagging behind.

The European Union has recently approved the new annual limit for PM_{2.5} (25 µg/m³) and a revision of the PM_{2.5} standard is foreseen for 2013. The EU conclusions have been controversial,²³ as adverse health effects have been detected at a much lower level of fine particles, as in the Helsinki study. There are 5 years to develop an approach that characterises sizes, properties and sources of PM, and evaluate health effects while

combining epidemiological, toxicological and clinical data.

Competing interests: None.

Thorax 2008;**63**:574–576. doi:10.1136/thx.2008.096073

REFERENCES

1. Pope CA 3rd, Dockery DW. Health effects of fine particulate air pollution: lines that connect. *J Air Waste Manag Assoc* 2006;**56**:709–42.
2. Oberdörster G. Pulmonary effects of inhaled ultrafine particles. *Int Arch Occup Environ Health* 2001;**74**:1–8.
3. Donaldson K, Stone V, Clouter A, et al. Ultrafine particles. *Occup Environ Med* 2001;**58**:211–16.
4. Halonen JI, Lanki T, Yli-Tuomi T, et al. Urban air pollution, and asthma and COPD hospital emergency room visits. *Thorax* 2008;**63**:635–41.
5. Peel J, Tolbert PE, Klein M, et al. Ambient air pollution and respiratory emergency department visits. *Epidemiology* 2005;**16**:164–74.
6. Andersen ZJ, Wahlin P, Raaschou-Nielsen O, et al. Size distribution and total number concentration of ultrafine and accumulation mode particles and hospital admissions in children and the elderly in Copenhagen, Denmark. *Occup Environ Med* 2007 Nov 7 (Epub ahead of print).
7. Mc Creanor J, Cullinan P, Nieuwenhuijsen MJ, et al. Respiratory effects of exposure to diesel traffic in persons with asthma. *N Engl J Med* 2007;**357**:2348–58.
8. Delfino RJ, Staimer N, Gillen D, et al. Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma. *Environ Health Perspect* 2006;**114**:1736–43.
9. Mortimer KM, Neas LM, Dockery DW, et al. The effect of air pollution on inner-city children with asthma. *Eur Respir J* 2002;**19**:699–705.
10. O'Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. *Thorax* 2006;**61**:354–61.
11. van Eeden SF, Yeung A, Auinlam K, et al. Systemic response to ambient particulate matter. Relevance to chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2005;**2**:61–7.
12. Zeka A, Sullivan JR, Vokonas PS, et al. Inflammatory markers and particulate air pollution: characterizing the pathway to disease. *Int J Epidemiol* 2006;**35**:1347–54.
13. Schwartz J. Air pollution and hospital admissions for respiratory disease. *Epidemiology* 1996;**7**:20–8.
14. Atkinson RW, Anderson HR, Sunyer J, et al. Acute effects of particulate air pollution on respiratory admissions. Results from APHEA 2 Project. *Am J Respir Crit Care Med* 2001;**164**:1860–6.
15. Dominici F, Peng RD, Bell ML, et al. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. *JAMA* 2006;**295**:1127–34.
16. Medina-Ramón M, Zanobetti A, Schwartz J. The effect of ozone and PM₁₀ on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study. *Am J Epidemiol* 2006;**163**:579–86.
17. Anderson HR, Bremner SA, Atkinson RW, et al. Particulate matter and daily mortality and hospital admissions in the west midlands conurbation of the United Kingdom: associations with fine and coarse particles, black smoke and sulphate. *Occup Environ Med* 2001;**58**:504–10.
18. Ko FW, Tam W, Wong TW, et al. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. *Thorax* 2007;**62**:780–5.
19. Kreyling WG, Möller W, Semmler-Behnke M, et al. Particles dosimetry: deposition and clearance from the respiratory tract and translocation towards extra-pulmonary sites. In: Donaldson K, Borm P. *Particles toxicology*. Boca Raton: CRC press, 2007:47–74.
20. Katsouyanni K, Zmirou D, Spix C, et al. Short-term effects of air pollution on health: a European approach using epidemiological time-series data. The APHEA project: background, objectives, design. *Eur Respir J* 1995;**8**:1030–8.

21. **World Health Organization.** *Health relevance of particulate matter from various sources.* Report on a WHO Workshop, Bonn, Germany, 26–27 March 2007. Copenhagen: World Health Organization, 2007.
22. **Bell ML,** Dominici F, Ebisu K, *et al.* Spatial and temporal variation in PM(2.5) chemical composition in the United States for health effects studies. *Environ Health Perspect* 2007;**115**:989–95.
23. **Annesi-Maesano I,** Forastiere F, Kunzli N, *et al.* Environment and Health Committee of the European Respiratory Society. Particulate matter, science and EU policy. *Eur Respir J* 2007;**29**:428–31.

Obesity and the respiratory physician

Fionnuala Crummy,¹ Matthew T Naughton,²
J Stuart Elborn^{1,3}

Respiratory medicine has developed as a specialty in the wake of a number of public health milestones. The origins of many of the learned societies associated with respiratory medicine can be traced back to the epidemic of tuberculosis (TB) in the early 19th century.¹ Effective public health and effective treatment regimes reduced the prevalence and mortality of TB. The seminal work linking the role of tobacco smoking and its detrimental effects on the lung² was the second key finding which challenged our specialty. Public health measures and the development of new treatments are reducing the prevalence of smoking-related lung disease, although there is still much work to be done. Obesity has emerged in the opening years of this century as a major challenge to public health. The impact of obesity on the prevalence and mortality of many diseases is well documented, although there has been little attention paid to its impact on respiratory disease.

Obesity rates are rising at an alarming rate in developed and developing countries, in both sexes, in children and adults. The obesity epidemic in children is particularly concerning as today's overweight children and adolescents will become tomorrow's obese adults.³ It has been estimated that childhood obesity observed now will lead to a reduction in life expectancy in the USA of between 2 and 5 years by the middle of this century—an effect equivalent to that of all cancers combined.⁴

Physicians recognise obesity or overweight poorly. A North American study examined the records of 424 overweight

or obese patients.⁵ Only 20% of patients were correctly identified by the treating physician as overweight or obese, in only 2% of cases was body mass index documented and only 16.5% of the patients received any obesity management advice (ranging from simple advice to referral for surgical management).

Obese patients provide particular diagnostic and management dilemmas to the respiratory physician, and these are explored in a series of five articles to be published over the coming months in *Thorax*. The first of these examines the epidemiology and possible aetiological links between obesity and lung disease (*see page 649*)⁶. Much work remains to move beyond epidemiological links to an understanding of the mechanisms underlying the associations demonstrated in asthma and obstructive sleep apnoea (OSA).

OSA has a similar prevalence to diabetes in the general population and, while not all patients with sleep apnoea are overweight, excess body weight is the major modifiable risk factor for the condition. Obesity hypoventilation syndrome is a common condition, resulting in impaired quality of life and high healthcare utilisation. If recognised, it can be effectively treated.

Patients in the intensive care unit who are obese have specific and practical management issues such as specific beds required to accommodate them safely, and challenges in transport and imaging. The specific issues which affect this group of patients—including the difficulties in airway management and the recognition of abdominal compartment syndrome—are discussed, along with practical suggestions for management.

Epidemiological studies have suggested that there are links between obesity and the development of asthma. The fourth article discusses potential mechanisms for this association, including the contribution of adipokines to the asthma phenotype and the reductions in peripheral airway

diameter in obesity. Obese patients with asthma use more health resources than their lean counterparts, possibly reflecting that obesity may make the asthma phenotype more resistant to treatment. Some of the commonly used drugs in respiratory medicine (eg, oral glucocorticoids) have important effects on body composition and ultimately on pulmonary mechanics, and this merits consideration in the risk/benefit ratio in their prescription.

It is known that loss of fat-free mass is a poor prognostic marker in severe chronic obstructive pulmonary disease (COPD). The effects of obesity in this condition are less well known, and this is discussed in the final article. While epidemiological studies have suggested that obesity may be protective in a number of chronic diseases including COPD, the pathophysiology of this observation is yet to be elucidated. COPD is associated with systemic inflammation and there is accumulating evidence that hypoxia may exacerbate this cascade. The final article discusses the intriguing possibility that obesity exerts different effects on various subgroups of patients with COPD and highlights areas requiring further research.

The interactions of nutrition with lung disease should be considered in everyone presenting with respiratory problems. All people with respiratory disease should have serial measures of weight on accurate well-calibrated scales, professionals should be educated in the management and recognition of obesity, patients should receive management and advice including access to well organised, readily available obesity services when required. The potential impact of obesity on pulmonary physiology should also be considered in people with other complications of obesity.

However, more important will be the urgent implementation of far-reaching public health measures designed to reduce the impact of obesity on future generations. These will include such measures as provision of routes to allow commuters to walk or cycle, regulation of advertising of junk food, access for increased physical activity, re-education of consumers regarding food choices and incentives for farmers to produce nutritious food.⁷

The combined advertising spending for Pepsi and Coca-Cola for 2004 was more

¹ Department of Respiratory Medicine, Belfast City Hospital, Belfast, UK; ² Alfred Hospital and Monash University Melbourne, Victoria, Australia; ³ Respiratory Medicine Research Group, Queen's University, Belfast, UK

Correspondence to: Professor J S Elborn, Respiratory Medicine Research Group, Queen's University, Belfast, Ground Floor, Belfast City Hospital, Belfast BT9 7AB, UK; stuart.elborn@belfasttrust.hscni.net